{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:31:35Z","timestamp":1790674295410,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,13]],"date-time":"2021-12-13T00:00:00Z","timestamp":1639353600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,12,13]],"date-time":"2021-12-13T00:00:00Z","timestamp":1639353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s40265-021-01650-7","type":"journal-article","created":{"date-parts":[[2021,12,13]],"date-time":"2021-12-13T04:18:41Z","timestamp":1639369121000},"page":"55-62","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":74,"title":["Ofatumumab: A Review in Relapsing Forms of Multiple Sclerosis"],"prefix":"10.1007","volume":"82","author":[{"given":"Connie","family":"Kang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah A.","family":"Blair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,13]]},"reference":[{"issue":"14","key":"1650_CR1","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1177\/1352458520970841","volume":"16","author":"C Walton","year":"2020","unstructured":"Walton C, King R, Rechtman L, et al. Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition. Mult Scler J. 2020;16(14):1816\u201321.","journal-title":"Mult Scler J"},{"key":"1650_CR2","unstructured":"National Institute for Health and Care Excellence. Multiple sclerosis in adults: management. 2019. https:\/\/www.nice.org.uk. Accessed 16 Nov 2021."},{"key":"1650_CR3","unstructured":"Multiple Sclerosis Coalition. The use of disease-modifying therapies in multiple sclerosis: principles and current evidence. 2019. https:\/\/ms-coalition.org. Accessed 16 Nov 2021."},{"key":"1650_CR4","doi-asserted-by":"publisher","first-page":"595547","DOI":"10.3389\/fneur.2020.595547","volume":"11","author":"CA Roach","year":"2020","unstructured":"Roach CA, Cross AH. Anti-CD20 B cell treatment for relapsing multiple sclerosis. Front Neurol. 2020;11:595547.","journal-title":"Front Neurol"},{"issue":"18","key":"1650_CR5","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.2217\/cer-2020-0122","volume":"9","author":"IA Samjoo","year":"2020","unstructured":"Samjoo IA, Worthington E, Drudge C, et al. Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis. J Comp Eff Res. 2020;9(18):1255\u201374.","journal-title":"J Comp Eff Res."},{"issue":"6","key":"1650_CR6","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1056\/NEJMoa1917246","volume":"383","author":"SL Hauser","year":"2020","unstructured":"Hauser SL, Bar-Or A, Cohen JA, et al. Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med. 2020;383(6):546\u201357.","journal-title":"N Engl J Med"},{"key":"1650_CR7","unstructured":"CMSC DMT Guideline Writing Group. The Consortium of Multiple Sclerosis Centers practical guidelines for the selection of disease-modifying therapies in multiple sclerosis. 2019. https:\/\/www.mscare.org. Accessed 16 Nov 2021."},{"issue":"8","key":"1650_CR8","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.2165\/11203850-000000000-00000","volume":"70","author":"M Sanford","year":"2010","unstructured":"Sanford M, McCormack PL. Ofatumumab. Drugs. 2010;70(8):1013\u20139.","journal-title":"Ofatumumab. Drugs."},{"key":"1650_CR9","unstructured":"Novartis Pharmaceuticals Corporation. KESIMPTA\u00ae (ofatumumab) injection, for subcutaneous use: US prescribing information. 2020. https:\/\/www.hcp.novartis.com\/products\/kesimpta\/rms. Accessed 16 Nov 2021."},{"key":"1650_CR10","unstructured":"European Medicines Agency. Kesimpta (ofatumumab): EU summary of product characteristics. 2021. https:\/\/www.ema.europa.eu. Accessed 16 Nov 2021."},{"key":"1650_CR11","unstructured":"Pharmaceuticals and Medical Devices Agency. Kesimpta subcutaneous injection 20mg pen: Japanese package insert. 2021. https:\/\/www.pmda.go.jp. Accessed 16 Nov 2021."},{"issue":"7","key":"1650_CR12","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1212\/WNL.0000000000000125","volume":"82","author":"PS Sorensen","year":"2014","unstructured":"Sorensen PS, Lisby S, Grove R, et al. Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study. Neurology. 2014;82(7):573\u201381.","journal-title":"Neurology"},{"key":"1650_CR13","doi-asserted-by":"publisher","DOI":"10.1177\/13524585211044479","author":"A Bar-Or","year":"2021","unstructured":"Bar-Or A, Wiendl H, Montalban X, et al. Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study. Mult Scler J. 2021. https:\/\/doi.org\/10.1177\/13524585211044479.","journal-title":"Mult Scler J"},{"key":"1650_CR14","doi-asserted-by":"publisher","DOI":"10.1177\/13524585211055934","author":"JI Kira","year":"2021","unstructured":"Kira JI, Nakahara J, Sazonov DV, et al. Effect of ofatumumab versus placebo in relapsing multiple sclerosis patients from Japan and Russia: phase 2 APOLITOS study. Mult Scler J. 2021. https:\/\/doi.org\/10.1177\/13524585211055934","journal-title":"Mult Scler J"},{"issue":"20","key":"1650_CR15","doi-asserted-by":"publisher","first-page":"e1805","DOI":"10.1212\/WNL.0000000000005516","volume":"90","author":"A Bar-Or","year":"2018","unstructured":"Bar-Or A, Grove RA, Austin DJ, et al. Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: the MIRROR study. Neurology. 2018;90(20):e1805\u201314.","journal-title":"Neurology"},{"issue":"Suppl 3","key":"1650_CR16","first-page":"210","volume":"26","author":"J Gartner","year":"2020","unstructured":"Gartner J, Hauser S, Bar-Or A, et al. Benefit-risk of ofatumumab in treatment-naive early relapsing multiple sclerosis patients [abstract no. P0192]. Mult Scler J. 2020;26(Suppl 3):210.","journal-title":"Mult Scler J"},{"key":"1650_CR17","doi-asserted-by":"crossref","unstructured":"Delgado S, Williams MJ, Bagger M, et al. Comparable ofatumumab treatment outcomes in patients across racial\/ethnic groups in the ASCLEPIOS I\/II and APOLITOS studies [abstract no. 4139 plus poster]. In: 73rd Annual Meeting of the American Academy of Neurology. 2021.","DOI":"10.1212\/WNL.96.15_supplement.4139"},{"issue":"Suppl 15","key":"1650_CR18","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1212\/WNL.94.15_supplement.2356","volume":"94","author":"S Hauser","year":"2020","unstructured":"Hauser S, Bar-Or A, Cohen JA, et al. B-cell depletion and efficacy outcomes with ofatumumab: subgroup analysis from the pooled phase 3 ASCLEPIOS I and II trials [abstract no. 2356]. Neurology. 2020;94(Suppl 15):2356.","journal-title":"Neurology"},{"issue":"Suppl 3","key":"1650_CR19","first-page":"272","volume":"26","author":"A Bar-Or","year":"2020","unstructured":"Bar-Or A, Schubert-Tennigkeit AA, Mairon N, et al. Dose-dependent tolerability of intravenous and subcutaneous ofatumumab in clinical studies [abstract no. P0316]. Mult Scler J. 2020;26(Suppl 3):272\u20133.","journal-title":"Mult Scler J"},{"key":"1650_CR20","unstructured":"European Medicines Agency. Kesimpta: EU public assessment report. 2021. https:\/\/www.ema.europa.eu. Accessed 16 Nov 2021."},{"key":"1650_CR21","unstructured":"Jasi\u0144ska E, Habek M, Wynn D, et al. Impact of ofatumumab on immune responses post-vaccination in RMS patients: ALITHIOS vaccination sub-study design [oral presentation OPR-207]. In: 7th Congress of the European Academy of Neurology. 2021."},{"key":"1650_CR22","doi-asserted-by":"crossref","unstructured":"Hellwig K, Yamout B, Bove R, et al. Pregnancy outcomes in patients with multiple sclerosis following exposure to ofatumumab. In: Consortium of Multiple Sclerosis Centers Annual Meeting. 2021.","DOI":"10.1016\/j.msard.2022.103632"},{"issue":"2","key":"1650_CR23","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1177\/1352458517751049","volume":"24","author":"X Montalban","year":"2018","unstructured":"Montalban X, Gold R, Thompson AJ, et al. ECTRIMS\/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler J. 2018;24(2):96\u2013120.","journal-title":"Mult Scler J"},{"key":"1650_CR24","doi-asserted-by":"publisher","first-page":"102162","DOI":"10.1016\/j.msard.2020.102162","volume":"43","author":"M Paz-Zuluetaab","year":"2020","unstructured":"Paz-Zuluetaab M, Par\u00e1s-Bravoa P, Cantarero-Prieto D, et al. A literature review of cost-of-illness studies on the economic burden of multiple sclerosis. Mult Scler Relat Disord. 2020;43:102162.","journal-title":"Mult Scler Relat Disord."},{"key":"1650_CR25","unstructured":"Canadian Agency for Drugs and Technologies. CADTH clinical review report: ofatumumab (Kesimpta). 2021. https:\/\/www.cadth.ca\/ofatumumab. Accessed 16 Nov 2021."},{"key":"1650_CR26","unstructured":"National Institute for Health and Care Excellence. Ofatumumab for treating relapsing multiple sclerosis: technology appraisal guidance [TA699]. 2021. https:\/\/www.nice.org.uk\/guidance\/ta699. Accessed 16 Nov 2021."},{"issue":"Suppl 1","key":"1650_CR27","first-page":"35","volume":"27","author":"A Ross","year":"2021","unstructured":"Ross A, Besser C, Naval S, et al. Patient and nurse preferences for Sensoready\u00ae autoinjector pen versus other autoinjectors in multiple sclerosis: results from a multicenter survey [abstract no. P210]. Mult Scler J. 2021;27(Suppl 1):35.","journal-title":"Mult Scler J"},{"key":"1650_CR28","unstructured":"Savelieva M, Kahn J, Bagger M, et al. Comparison of the B-cell recovery time following discontinuation of anti-CD20 therapies [abstract no. EP1624]. In: 7th Joint European Committee for Treatment and Research in Multiple Sclerosis-Americas Committee for Treatment and Research in Multiple Sclerosis. 2017."}],"updated-by":[{"DOI":"10.1007\/s40265-021-01669-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,12,29]],"date-time":"2021-12-29T00:00:00Z","timestamp":1640736000000}}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01650-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-021-01650-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01650-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T08:11:19Z","timestamp":1726301479000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-021-01650-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,13]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["1650"],"URL":"https:\/\/doi.org\/10.1007\/s40265-021-01650-7","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40265-021-01669-w","asserted-by":"object"}]},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,13]]},"assertion":[{"value":"13 December 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2021","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40265-021-01669-w","URL":"https:\/\/doi.org\/10.1007\/s40265-021-01669-w","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Connie Kang and Hannah Blair are salaried employees of Adis International Ltd\/Springer Nature, and declare no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent for publication, Availability of data and material, Code availability"}}]}}